BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines External R&D by Year
External R&D — Tacabrutideg (BGB-16673, BTK CDAC) ($M) ($M)
BeOne Medicines External R&D: $93.8M in FY2025, up 360.3% from a year earlier.
Latest, FY2025
93.8
Period ended Dec 31, 2025
Change on a year earlier
+360.3%
20.4 in FY2024
History
4 years
Since FY2022
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| BGB-16673 (BTK-targeted CDAC) | 93,801 | 20,380”
Reported in Form 8-K EX-99.1 SSE STAR Market Annual Reports (688235.SS).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | External R&D — Tacabrutideg (BGB-16673, BTK CDAC) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 93.8 | +360.3% | 8-K STAR Report (2026-04-14, 0001651308-26-000008) ↗ |
| FY2024 | Dec 31, 2024 | 20.4 | +468.6% | 8-K STAR Report (2026-04-14, 0001651308-26-000008) ↗ |
| FY2023 | Dec 31, 2023 | 3.58 | +234.6% | 8-K STAR Report (2025-04-28, 0001651308-25-000057) ↗ |
| FY2022 | Dec 31, 2022 | 1.07 | – | 8-K STAR Report (2024-04-26, 0001651308-24-000043) ↗ |
Cite this data
StockData. (2026). BeOne Medicines External R&D ($M), annual FY2022–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd-mol-bgb16673
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.